Rituximab for plasma exchange-dependent recurrent focal segmental glomerulosclerosis after renal transplantation
نویسندگان
چکیده
Focal segmental glomerulosclerosis (FSGS) can recur after renal transplantation and is associated with a reduced graft survival. In the case of recurrent FSGS, treatment with plasma exchange (PE) results in a remission of proteinuria in up to 85% of patients, especially if started shortly after the onset of recurrence [1,2]. However, many patients require repeated courses of PE because of frequent relapses [1,3]. Recently, a 7-year-old boy with recurrent FSGS after renal transplantation responded to rituximab, a monoclonal antiCD20 antibody, that was administered for a transplantationrelated lymphoma [4]. Following this report, several other cases with recurrent FSGS after renal transplantation were published, showing varying degrees of success after treatment with rituximab [5]. We describe the results of treatment with rituximab in a 24-year-old female patient, with recurrent FSGS after renal transplantation.
منابع مشابه
Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis
Recurrent focal segmental glomerulosclerosis (FSGS) after renal transplantation is difficult to treat. Recently a series of four patients unresponsive to plasma exchange (PE) and rituximab, who were successfully treated with abatacept, has been reported. We present a 26-year-old Caucasian patient who suffered from juvenile rheumatoid arthritis and developed severe proteinuria eleven days after ...
متن کاملTreatment of Recurrent Focal Segmental Glomerulosclerosis in Pediatric Kidney Transplant Recipients: Effect of Rituximab
Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation is a complication that often leads to graft loss. There is no consensus on the optimal treatment of recurrent FSGS. Rituximab, a monoclonal antibody to CD20, may be a useful treatment of this complication. Methods. We report four pediatric cases of recurrent FSGS treated with rituximab and plasmapheresis. Result...
متن کاملKidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence.
BACKGROUND For a subset of adults and children with primary focal segmental glomerulosclerosis (FSGS), proteinuria and renal dysfunction recur after kidney transplantation (KTx). Predicting recurrence and response to plasmapheresis (PP) or other interventions remains problematic. METHODS The prevalence, recurrence rate, outcomes, and treatment responses of patients with FSGS were determined a...
متن کاملUnsuccessful Treatment with Abatacept in Recurrent Focal Segmental Glomerulosclerosis after Kidney Transplantation
Recurrence of focal segmental glomerulosclerosis (FSGS) after renal transplantation occurs in up to 20-50% of FSGS patients and is associated with inferior allograft survival. Treatment of both primary FSGS as well as recurrent FSGS after transplantation with plasma exchange and immunosuppression is often unsuccessful and remains a major challenge as the disease still leads to end-stage renal d...
متن کاملRituximab therapy in early recurrent focal segmental sclerosis after renal transplantation.
Kidney transplants may be lost due to recurrence of the primary disease. In glomerulonephritis, all kinds taken together, 3% of the patients lose their grafts due to recurrence [1]. If, however, a first kidney graft has been lost from recurrence, the rate of failure caused by recurrence in subsequent grafts is ∼48% [1]. Focal segmental glomerulosclerosis (FSGS) in a young patient is associated ...
متن کامل